IBDEI1XJ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30823,1,4,0)
 ;;=4^T86.10
 ;;^UTILITY(U,$J,358.3,30823,2)
 ;;=^5055708
 ;;^UTILITY(U,$J,358.3,30824,0)
 ;;=T86.11^^123^1593^6
 ;;^UTILITY(U,$J,358.3,30824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30824,1,3,0)
 ;;=3^Kidney Transplant Rejection
 ;;^UTILITY(U,$J,358.3,30824,1,4,0)
 ;;=4^T86.11
 ;;^UTILITY(U,$J,358.3,30824,2)
 ;;=^5055709
 ;;^UTILITY(U,$J,358.3,30825,0)
 ;;=T86.12^^123^1593^4
 ;;^UTILITY(U,$J,358.3,30825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30825,1,3,0)
 ;;=3^Kidney Transplant Failure
 ;;^UTILITY(U,$J,358.3,30825,1,4,0)
 ;;=4^T86.12
 ;;^UTILITY(U,$J,358.3,30825,2)
 ;;=^5055710
 ;;^UTILITY(U,$J,358.3,30826,0)
 ;;=T86.13^^123^1593^5
 ;;^UTILITY(U,$J,358.3,30826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30826,1,3,0)
 ;;=3^Kidney Transplant Infection
 ;;^UTILITY(U,$J,358.3,30826,1,4,0)
 ;;=4^T86.13
 ;;^UTILITY(U,$J,358.3,30826,2)
 ;;=^5055711
 ;;^UTILITY(U,$J,358.3,30827,0)
 ;;=Z94.0^^123^1593^7
 ;;^UTILITY(U,$J,358.3,30827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30827,1,3,0)
 ;;=3^Kidney Transplant Status
 ;;^UTILITY(U,$J,358.3,30827,1,4,0)
 ;;=4^Z94.0
 ;;^UTILITY(U,$J,358.3,30827,2)
 ;;=^5063654
 ;;^UTILITY(U,$J,358.3,30828,0)
 ;;=Z48.22^^123^1593^1
 ;;^UTILITY(U,$J,358.3,30828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30828,1,3,0)
 ;;=3^Aftercare Following Kidney Transplant
 ;;^UTILITY(U,$J,358.3,30828,1,4,0)
 ;;=4^Z48.22
 ;;^UTILITY(U,$J,358.3,30828,2)
 ;;=^5063039
 ;;^UTILITY(U,$J,358.3,30829,0)
 ;;=Z52.4^^123^1593^2
 ;;^UTILITY(U,$J,358.3,30829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30829,1,3,0)
 ;;=3^Kidney Donor
 ;;^UTILITY(U,$J,358.3,30829,1,4,0)
 ;;=4^Z52.4
 ;;^UTILITY(U,$J,358.3,30829,2)
 ;;=^5063082
 ;;^UTILITY(U,$J,358.3,30830,0)
 ;;=D47.Z1^^123^1593^8
 ;;^UTILITY(U,$J,358.3,30830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30830,1,3,0)
 ;;=3^Post-Transplant Lymphoproliferative Disorder (PTLD)
 ;;^UTILITY(U,$J,358.3,30830,1,4,0)
 ;;=4^D47.Z1
 ;;^UTILITY(U,$J,358.3,30830,2)
 ;;=^5002261
 ;;^UTILITY(U,$J,358.3,30831,0)
 ;;=N18.1^^123^1594^1
 ;;^UTILITY(U,$J,358.3,30831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30831,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,30831,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,30831,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,30832,0)
 ;;=N18.2^^123^1594^2
 ;;^UTILITY(U,$J,358.3,30832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30832,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,30832,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,30832,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,30833,0)
 ;;=N18.3^^123^1594^3
 ;;^UTILITY(U,$J,358.3,30833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30833,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3
 ;;^UTILITY(U,$J,358.3,30833,1,4,0)
 ;;=4^N18.3
 ;;^UTILITY(U,$J,358.3,30833,2)
 ;;=^5015604
 ;;^UTILITY(U,$J,358.3,30834,0)
 ;;=N18.4^^123^1594^4
 ;;^UTILITY(U,$J,358.3,30834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30834,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,30834,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,30834,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,30835,0)
 ;;=N18.5^^123^1594^5
 ;;^UTILITY(U,$J,358.3,30835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30835,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,30835,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,30835,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,30836,0)
 ;;=N18.9^^123^1594^6
